Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Zile MR"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 37
Tytuł:
Biologically derived epicardial patch induces macrophage mediated pathophysiologic repair in chronically infarcted swine hearts.
Autorzy:
Lancaster JJ; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Grijalva A; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Fink J; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.
Ref J; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Daugherty S; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Whitman S; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Fox K; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.; Division of Cardiothoracic Surgery, Department of Surgery, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Gorman G; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Lancaster LD; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Avery R; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Acharya T; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
McArthur A; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Strom J; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Pierce MK; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Moukabary T; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Borgstrom M; Research & Discovery Tech, Research Computing Specialist, Principal, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Benson D; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.
Mangiola M; Department of Pathology, NYU Grossman School of Medicine, New York City, NY, 11016, USA.
Pandey AC; Section of Cardiology, Tulane University Heart and Vascular Institute, John W. Deming Department of Medicine, Section of Cardiology, Department of Medicine, Southeast Louisiana Veterans Healthcare System, Tulane University School of Medicine, New Orleans, LA, 70122, USA.
Zile MR; Ralph H. Johnson VA Medical Center, Division of Cardiology, Medical University of South Carolina, Thurmond/Gazes Building, 30 Courtenay Drive, Charleston, SC, 29425, USA.
Bradshaw A; Ralph H. Johnson VA Medical Center, Division of Cardiology, Medical University of South Carolina, Thurmond/Gazes Building, 30 Courtenay Drive, Charleston, SC, 29425, USA.
Koevary JW; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA.; Biomedical Engineering, College of Engineering, University of Arizona, 1127 E. James E. Rogers Way, Tucson, AZ, 85721, USA.
Goldman S; Sarver Heart Center, Department of Medicine, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ, 85724, USA. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2023 Nov 25; Vol. 6 (1), pp. 1203. Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myocardial Infarction*/pathology
Myocardial Infarction*/therapy
Heart Failure*/metabolism
Rats ; Mice ; Humans ; Animals ; Swine ; Myocytes, Cardiac/metabolism ; Ventricular Function, Left ; Macrophages/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Health-related quality of life outcomes in PARAGON-HF.
Autorzy:
Chandra A; Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Polanczyk CA; Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Claggett BL; Brigham and Women's Hospital, Boston, MA, USA.
Vaduganathan M; Brigham and Women's Hospital, Boston, MA, USA.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Lefkowitz MP; Novartis, East Hanover, NJ, USA.
Rouleau JL; Institut de Cardiologie de Montreal, Université de Montreal Canada, Montreal, Canada.
Liu J; Brigham and Women's Hospital, Boston, MA, USA.
Shi VC; Novartis, East Hanover, NJ, USA.
Schwende H; Novartis, East Hanover, NJ, USA.
Zile MR; RHJ Department of Veterans Administration Medical Center, Medical University of South Carolina, Charleston, SC, USA.
Desai AS; Brigham and Women's Hospital, Boston, MA, USA.
Pfeffer MA; Brigham and Women's Hospital, Boston, MA, USA.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Solomon SD; Brigham and Women's Hospital, Boston, MA, USA.
Lewis EF; Cardiovascular Division, Stanford University School of Medicine, Palo Alto, CA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Dec; Vol. 24 (12), pp. 2264-2274. Date of Electronic Publication: 2022 Dec 09.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/drug therapy
Heart Failure*/chemically induced
Humans ; Quality of Life ; Tetrazoles/therapeutic use ; Angiotensin Receptor Antagonists/therapeutic use ; Stroke Volume ; Valsartan/therapeutic use ; Aminobutyrates/therapeutic use ; Biphenyl Compounds/therapeutic use ; Drug Combinations
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials.
Autorzy:
Coats AJS; University of Warwick, Coventry, UK.
Abraham WT; Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH, USA.
Zile MR; The Medical University of South Carolina and the RHJ Department of Veterans Affairs Medical Center, Charleston, SC, USA.
Lindenfeld JA; Vanderbilt Heart and Vascular Institute, Nashville, TN, USA.
Weaver FA; Division of Vascular Surgery and Endovascular Therapy, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Fudim M; Duke University Medical Center, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
Bauersachs J; Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
Duval S; Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN, USA.
Galle E; CVRx®, Inc., Minneapolis, MN, USA.
Zannad F; Université de Lorraine, Inserm Centre d'Investigation, CHU, Université de Lorraine, Nancy, France.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Sep; Vol. 24 (9), pp. 1665-1673. Date of Electronic Publication: 2022 Jul 03.
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Electric Stimulation Therapy*/methods
Heart Failure*/diagnosis
Heart Failure*/therapy
Baroreflex/physiology ; Humans ; Natriuretic Peptide, Brain ; Peptide Fragments ; Quality of Life ; Randomized Controlled Trials as Topic ; Stroke Volume/physiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
Autorzy:
Curtain JP; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Jackson AM; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Shen L; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Division of Health Sciences, Hangzhou Normal University, Hangzhou, China.
Jhund PS; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Docherty KF; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Petrie MC; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Castagno D; Division of Cardiology, Città della Salute e della Scienza Hospital, Department of Medical Sciences, University of Turin, Torino, Italy.
Desai AS; Division of Cardiovascular, Brigham and Women's Hospital, Boston, MA, USA.
Rohde LE; Division of Cardiovascular, Brigham and Women's Hospital, Boston, MA, USA.; Hospital de Clínicas de Porto Alegre and UFRGS Medical School, Porto Alegre, Brazil.
Lefkowitz MP; Novartis, East Hanover, NJ, USA.
Rouleau JL; Institut de Cardiologie de Montréal, Université de Montréal, Montreal, Canada.
Zile MR; Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA.
Solomon SD; Division of Cardiovascular, Brigham and Women's Hospital, Boston, MA, USA.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Mar; Vol. 24 (3), pp. 551-561. Date of Electronic Publication: 2022 Jan 19.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Heart Failure*
Aminobutyrates/pharmacology ; Aminobutyrates/therapeutic use ; Angiotensin Receptor Antagonists/adverse effects ; Arrhythmias, Cardiac/complications ; Biphenyl Compounds ; Drug Combinations ; Humans ; Stroke Volume ; Tetrazoles/pharmacology ; Tetrazoles/therapeutic use ; Valsartan
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction.
Autorzy:
Jackson AM; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Rørth R; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Heart Centre, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Liu J; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Kristensen SL; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Heart Centre, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Anand IS; University of Minnesota, Minneapolis, MN, USA.
Claggett BL; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Cleland JGF; Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Chopra VK; Max Super Speciality Hospital, Saket, New Delhi, India.
Desai AS; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Ge J; Shanghai Institute of Cardiovascular Diseases, Shanghai, China.
Gong J; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Lam CSP; National Heart Center Singapore and Duke-National University of Singapore, Singapore, Singapore.; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Lefkowitz MP; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Maggioni AP; National Association of Hospital Cardiologists Research Center, Florence, Italy.
Martinez F; National University of Cordoba, Cordoba, Argentina.
Packer M; Baylor University Medical Center, Dallas, TX, USA.
Pfeffer MA; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Pieske B; Department of Internal Medicine and Cardiology, German Center for Cardiovascular Research partner site Berlin, Berlin, Germany.
Redfield MM; Mayo Clinic, Rochester, MN, USA.
Rizkala AR; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Rouleau JL; Institut de Cardiologie de Montréal, Université de Montréal, Montreal, Canada.
Seferović PM; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Tromp J; National Heart Center Singapore and Duke-National University of Singapore, Singapore, Singapore.; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Van Veldhuisen DJ; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Yilmaz MB; Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Zannad F; INSERM Centre d'Investigation Clinic 1433 and Universite de Lorraine, Centre Hospitalier Regional et Universitaire, Nancy, France.
Zile MR; Medical University of South Carolina and the Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA.
Køber L; Heart Centre, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Petrie MC; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Jhund PS; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Solomon SD; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Corporate Authors:
PARAGON-HF Committees and Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Mar; Vol. 24 (3), pp. 497-509. Date of Electronic Publication: 2022 Jan 04.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Diabetes Mellitus*/epidemiology
Heart Failure*/drug therapy
Prediabetic State*/epidemiology
Humans ; Middle Aged ; Natriuretic Peptide, Brain/therapeutic use ; Peptide Fragments/therapeutic use ; Prognosis ; Stroke Volume ; Ventricular Function, Left
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF.
Autorzy:
Zhang Y; Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Van Laer AO; Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Baicu CF; Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Neff LS; Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Hoffman S; Division of Rheumatology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Katz MR; Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Zeigler SM; Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Zile MR; Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina, United States of America.
Bradshaw AD; Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Jan 11; Vol. 17 (1), pp. e0262479. Date of Electronic Publication: 2022 Jan 11 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Biomarkers/*metabolism
Fibroblasts/*pathology
Fibrosis/*pathology
Heart Failure/*pathology
Heart Ventricles/*pathology
Hypertension/*physiopathology
Myocardium/*pathology
Aged ; Case-Control Studies ; Cell Proliferation ; Cells, Cultured ; Female ; Fibroblasts/metabolism ; Fibrosis/metabolism ; Heart Failure/metabolism ; Heart Ventricles/metabolism ; Humans ; Male ; Middle Aged ; Myocardium/metabolism ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
Autorzy:
Suzuki K; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Claggett B; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Minamisawa M; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Zile MR; Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA.
Pfeffer MA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Chiang LM; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Lefkowitz M; Novartis Pharmaceuticals, East Hanover, NJ, USA.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Solomon SD; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Desai AS; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2021 Dec; Vol. 23 (12), pp. 2085-2090. Date of Electronic Publication: 2021 Jul 01.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiotensin Receptor Antagonists*/adverse effects
Heart Failure*
Aminobutyrates/pharmacology ; Aminobutyrates/therapeutic use ; Biphenyl Compounds ; Drug Combinations ; Humans ; Stroke Volume/physiology ; Tetrazoles/pharmacology ; Tetrazoles/therapeutic use ; Valsartan
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.
Autorzy:
Bhatt AS; Division of Cardiology, Brigham and Women's Hospital, Boston, MA, USA.
Vaduganathan M; Division of Cardiology, Brigham and Women's Hospital, Boston, MA, USA.
Claggett BL; Division of Cardiology, Brigham and Women's Hospital, Boston, MA, USA.
Liu J; Division of Cardiology, Brigham and Women's Hospital, Boston, MA, USA.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Desai AS; Division of Cardiology, Brigham and Women's Hospital, Boston, MA, USA.
Lefkowitz MP; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Rouleau JL; Montreal Heart Institute, Université de Montréal, Montréal, QC, Canada.
Shi VC; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Zile MR; Medical University of South Carolina, Charleston and Ralph H. Johnston Veterans Administration Medical Center, Charleston, SC, USA.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Vardeny O; Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, and University of Minnesota, Minneapolis, MN, USA.
McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Solomon SD; Division of Cardiology, Brigham and Women's Hospital, Boston, MA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2021 Sep; Vol. 23 (9), pp. 1518-1524. Date of Electronic Publication: 2021 Jun 21.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Enalapril*
Heart Failure*/drug therapy
Aminobutyrates ; Angiotensin Receptor Antagonists ; Biphenyl Compounds ; Drug Combinations ; Humans ; Stroke Volume ; Tetrazoles ; Treatment Outcome ; Valsartan
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
Autorzy:
Ferreira JP; National Institute of Health and Medical Research, Center for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Claggett BL; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Liu J; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Desai AS; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Pfeffer MA; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Anand IS; Department of Cardiovascular Medicine, University of Minnesota, Minneapolis, MN, USA.
van Veldhuisen DJ; Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Kober L; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Cleland JGF; Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow, UK.
Rouleau JL; Montreal Institute of Cardiology, University of Montreal, Montreal, Canada.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.; Imperial College, London, UK.
Zile MR; Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston, SC, USA.
Shi VC; Novartis, East Hanover, NJ, USA.
Lefkowitz MP; Novartis, East Hanover, NJ, USA.
Shah SJ; Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Vardeny O; Minneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis, MN, USA.
Zannad F; National Institute of Health and Medical Research, Center for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.
Solomon SD; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2021 May; Vol. 23 (5), pp. 776-784. Date of Electronic Publication: 2021 Mar 08.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*
Aged ; Aminobutyrates ; Angiotensin Receptor Antagonists ; Female ; Humans ; Potassium ; Stroke Volume ; Valsartan
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE.
Autorzy:
Kristensen SL; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Department of Cardiology, Rigshospitalet University Hospital, Copenhagen, Denmark.
Castagno D; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Division of Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy.
Shen L; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Jhund PS; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Docherty KF; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Rørth R; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Department of Cardiology, Rigshospitalet University Hospital, Copenhagen, Denmark.
Abraham WT; Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA.
Desai AS; Cardiovascular Medicine, Brigham and Women's Hospital, Boston MA, USA.
Dickstein K; Stavanger University Hospital, Stavanger, and the Institute of Internal Medicine, University of Bergen, Bergen, Norway.
Rouleau JL; Institut de Cardiologie, Université de Montréal, Montréal, Canada.
Zile MR; Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston, SC, USA.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA and National Heart and Lung Institute, Imperial College, London.
Solomon SD; Cardiovascular Medicine, Brigham and Women's Hospital, Boston MA, USA.
Køber L; Department of Cardiology, Rigshospitalet University Hospital, Copenhagen, Denmark.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Corporate Authors:
PARADIGM-HF and ATMOSPHERE Committees and Investigators.
Źródło:
European journal of heart failure [Eur J Heart Fail] 2020 Dec; Vol. 22 (12), pp. 2370-2379. Date of Electronic Publication: 2020 Sep 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Bundle-Branch Block*/diagnosis
Bundle-Branch Block*/epidemiology
Bundle-Branch Block*/mortality
Bundle-Branch Block*/therapy
Cardiac Resynchronization Therapy*
Heart Failure*/mortality
Heart Failure*/physiopathology
Heart Failure*/therapy
Aged ; Electrocardiography ; Female ; Heart Conduction System/physiopathology ; Hospitalization ; Humans ; Incidence ; Male ; Middle Aged ; Prevalence ; Prognosis ; Randomized Controlled Trials as Topic ; Stroke Volume/physiology ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
Autorzy:
Selvaraj S; Division of Cardiology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Claggett BL; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Pfeffer MA; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Desai AS; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Mc Causland FR; Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
McGrath MM; Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Anand IS; Department of Cardiovascular Medicine, University of Minnesota, Minneapolis, MN, USA.
van Veldhuisen DJ; Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Kober L; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Janssens S; Department of Cardiology, University Hospitals, Leuven, Belgium.
Cleland JGF; Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow, UK.
Pieske B; Department of Internal Medicine and Cardiology, German Centre for Cardiovascular Research partner site Berlin, Berlin, Germany.
Rouleau JL; Montreal Institute of Cardiology, University of Montreal, Montreal, QC, Canada.
Zile MR; Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston, SC, USA.
Shi VC; Novartis, East Hanover, NJ, USA.
Lefkowitz MP; Novartis, East Hanover, NJ, USA.
McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Solomon SD; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2020 Nov; Vol. 22 (11), pp. 2093-2101. Date of Electronic Publication: 2020 Sep 30.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Aminobutyrates*/therapeutic use
Biphenyl Compounds*/therapeutic use
Heart Failure*/blood
Heart Failure*/drug therapy
Heart Failure*/physiopathology
Uric Acid*/blood
Valsartan*/therapeutic use
Aged ; Aged, 80 and over ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Drug Combinations ; Female ; Humans ; Male ; Prospective Studies ; Randomized Controlled Trials as Topic ; Stroke Volume/drug effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Serum potassium in the PARADIGM-HF trial.
Autorzy:
Ferreira JP; National Institute of Health and Medical Research, Centre for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Mogensen UM; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Jhund PS; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Desai AS; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Rouleau JL; Montreal Heart Institute, Montreal, QC, Canada.
Zile MR; Medical University of South Carolina and Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA.
Rossignol P; National Institute of Health and Medical Research, Centre for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.
Zannad F; National Institute of Health and Medical Research, Centre for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Solomon SD; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2020 Nov; Vol. 22 (11), pp. 2056-2064. Date of Electronic Publication: 2020 Sep 29.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Aminobutyrates*/therapeutic use
Biphenyl Compounds*/therapeutic use
Enalapril*/therapeutic use
Heart Failure*/blood
Heart Failure*/drug therapy
Heart Failure*/physiopathology
Potassium*/blood
Valsartan*/therapeutic use
Aged ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Drug Combinations ; Female ; Humans ; Male ; Randomized Controlled Trials as Topic ; Stroke Volume/drug effects ; Ventricular Function, Left
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE.
Autorzy:
Dewan P; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Jackson A; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Jhund PS; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Shen L; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Ferreira JP; National Institute of Health and Medical Research (INSERM), Center for Clinical Multidisciplinary Research 1433, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network (F-CRIN) Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (INI-CRCT), Nancy, France.
Petrie MC; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Abraham WT; Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA.
Desai AS; Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Dickstein K; University of Bergen, Stavanger University Hospital, Stavanger, Norway.
Køber L; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Rouleau JL; Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Canada.
Solomon SD; Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden and National Heart.
Zile MR; Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2020 Nov; Vol. 22 (11), pp. 2123-2133. Date of Electronic Publication: 2020 Apr 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Frailty*/diagnosis
Frailty*/epidemiology
Frailty*/physiopathology
Heart Failure*/epidemiology
Heart Failure*/physiopathology
Female ; Hospitalization ; Humans ; Male ; Prevalence ; Quality of Life ; Stroke Volume
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
Autorzy:
Suzuki K; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Claggett B; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Minamisawa M; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Zile MR; Medical University of South Carolina and Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA.
Rouleau J; University of Montreal, Montreal, Quebec, Canada.
Swedberg K; University of Gothenburg, Gothenburg, Sweden.
Lefkowitz M; Novartis, East Hanover, NJ, USA.
Shi V; Novartis, East Hanover, NJ, USA.
McMurray JJV; University of Glasgow, Glasgow, UK.
Zucker SD; Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA.
Solomon SD; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2020 Sep; Vol. 22 (9), pp. 1662-1671. Date of Electronic Publication: 2020 May 14.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/drug therapy
Angiotensin Receptor Antagonists/*therapeutic use
Aminobutyrates ; Biphenyl Compounds ; Drug Combinations ; Humans ; Liver ; Prognosis ; Stroke Volume ; Valsartan
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction.
Autorzy:
Docherty KF; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Shen L; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Castagno D; Division of Cardiology, Città della Salute e della Scienza Hospital, Department of Medical Sciences, University of Turin, Torino, Italy.
Petrie MC; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Abraham WT; Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA.
Böhm M; Department of Internal Medicine III, University Hospital of Saarland, Saarland University, Homburg/Saar, Germany.
Desai AS; Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Dickstein K; Department of Cardiology, University of Bergen, Stavanger University Hospital, Stavanger, Norway.
Køber LV; Department of Cardiology, The Heart Centre, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Rouleau JL; Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Canada.
Solomon SD; Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden; National Heart and Lung Institute, Imperial College London, London, UK.
Vazir A; Department of Cardiology, Royal Brompton Hospital, National Heart and Lung Institute, Imperial College London, London, UK.
Zile MR; Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Jhund PS; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2020 Mar; Vol. 22 (3), pp. 528-538. Date of Electronic Publication: 2019 Dec 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Atrial Fibrillation*/epidemiology
Heart Failure*/epidemiology
Heart Rate ; Hospitalization ; Humans ; Natriuretic Peptide, Brain ; Peptide Fragments ; Prognosis ; Quality of Life ; Stroke Volume
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.
Autorzy:
Shen L; Department of Cardiology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Rørth R; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Cosmi D; Department of Cardiology, Hospital of Gubbio, Gubbio, Italy.
Kristensen SL; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Petrie MC; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Cosmi F; Department of Cardiology, Hospital of Cortona, Cortona, Italy.
Latini R; Department of Cardiovascular Research, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Køber L; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Anand IS; Department of Medicine, University of Minnesota Medical School and VA Medical Center, Minneapolis, MN, USA.
Carson PE; Department of Cardiology, Washington VA Medical Center, Washington, DC, USA.
Granger CB; Duke Clinical Research Institute, Duke University, Durham, NC, USA.
Komajda M; Department of Cardiology, Hospital Saint Joseph, Paris, France.
McKelvie RS; Western University, London, Ontario, Canada.
Solomon SD; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Staszewsky L; Department of Cardiovascular Research, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.; National Heart and Lung Institute, Imperial College London, London, UK.
Huynh T; McGill Health University Center, Division of Cardiology, Montreal, Quebec, Canada.
Zile MR; Medical University of South Carolina and Ralph H. Johnston Veterans Administration Medical Center, Charleston, SC, USA.
Jhund PS; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2019 Aug; Vol. 21 (8), pp. 974-984. Date of Electronic Publication: 2019 Jul 04.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Diabetes Mellitus, Type 2/*drug therapy
Heart Failure/*physiopathology
Insulin/*therapeutic use
Stroke Volume/*physiology
Ventricular Function, Left/*physiology
Aged ; Cause of Death/trends ; Diabetes Mellitus, Type 2/complications ; Female ; Global Health ; Heart Failure/diagnosis ; Heart Failure/mortality ; Hospitalization/trends ; Humans ; Hypoglycemic Agents/therapeutic use ; Male ; Middle Aged ; Prognosis ; Quality of Life ; Survival Rate/trends
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.
Autorzy:
Dewan P; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Jhund PS; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Shen L; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Petrie MC; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Abraham WT; Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA.
Atif Ali M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Chen CH; Department of Medicine, National Yang-Ming University School of Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.
Desai AS; Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Dickstein K; University of Bergen, Stavanger University Hospital, Stavanger, Norway.
Huang J; Department of Cardiology, First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Kiatchoosakun S; Cardiology, Medicine, Khon Kaen University, Khon Kaen, Thailand.
Kim KS; Daegu Catholic University Medical Centre, Daegu, South Korea.
Køber L; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Lai WT; Division of Cardiology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Liao Y; Institute of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Mogensen UM; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Oh BH; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Centre, Dallas, TX, USA.
Rouleau JL; Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Canada.
Shi V; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Sibulo AS Jr; St. Luke's Medical Centre, Quezon City, Philippines.
Solomon SD; Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Sritara P; Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.; National Heart and Lung Institute, Imperial College, London, UK.
Tsutsui H; Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Zile MR; Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Centre, Charleston, SC, USA.
McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2019 May; Vol. 21 (5), pp. 577-587. Date of Electronic Publication: 2018 Dec 10.
Typ publikacji:
Journal Article
MeSH Terms:
Practice Patterns, Physicians'*
Stroke Volume*
Cardiovascular Diseases/*mortality
Heart Failure/*therapy
Hospitalization/*statistics & numerical data
Adrenergic beta-Antagonists/therapeutic use ; Age Distribution ; Aged ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Asia/epidemiology ; Asia, Southeastern/epidemiology ; Asia, Western/epidemiology ; Cardiac Resynchronization Therapy Devices ; Cardiotonic Agents/therapeutic use ; Digoxin/therapeutic use ; Disease Management ; Diuretics/therapeutic use ; Europe/epidemiology ; Europe, Eastern/epidemiology ; Asia, Eastern/epidemiology ; Female ; Heart Failure/epidemiology ; Heart Failure/physiopathology ; Heart-Assist Devices ; Humans ; Latin America/epidemiology ; Male ; Middle Aged ; Mineralocorticoid Receptor Antagonists/therapeutic use ; North America/epidemiology ; Pacemaker, Artificial ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
Autorzy:
Vardeny O; Center for Care Delivery and Outcomes Research, VA Health Care System, Minneapolis, MN, USA.; Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Claggett B; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard University, Boston, MA, USA.
Kachadourian J; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Desai AS; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard University, Boston, MA, USA.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Rouleau J; Montreal Heart Institute and University of Montreal, Montreal, Québec, Canada.
Zile MR; Department of Medicine, Medical University of South Carolina, and the RHJ Department of Veterans Affairs Medical Center, Charleston, SC, USA.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Lefkowitz M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Shi V; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
McMurray JJV; British Heart Foundation and Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Solomon SD; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard University, Boston, MA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2019 Mar; Vol. 21 (3), pp. 337-341. Date of Electronic Publication: 2019 Feb 11.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Aminobutyrates*/administration & dosage
Aminobutyrates*/pharmacokinetics
Enalapril*/administration & dosage
Enalapril*/pharmacokinetics
Furosemide*/administration & dosage
Furosemide*/pharmacokinetics
Heart Failure*/drug therapy
Heart Failure*/physiopathology
Stroke Volume*
Tetrazoles*/administration & dosage
Tetrazoles*/pharmacokinetics
Aged ; Angiotensin Receptor Antagonists/administration & dosage ; Angiotensin Receptor Antagonists/pharmacokinetics ; Biological Availability ; Biphenyl Compounds ; Dose-Response Relationship, Drug ; Drug Combinations ; Drug Monitoring/methods ; Drug Monitoring/statistics & numerical data ; Female ; Humans ; Male ; Medication Therapy Management/statistics & numerical data ; Middle Aged ; Outcome Assessment, Health Care ; Sodium Potassium Chloride Symporter Inhibitors/administration & dosage ; Sodium Potassium Chloride Symporter Inhibitors/pharmacokinetics ; Valsartan
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Heart failure with preserved ejection fraction in Asia.
Autorzy:
Tromp J; National Heart Centre Singapore, Singapore, Singapore.; Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.; Duke-NUS Medical School, Singapore, Singapore.
Teng TH; National Heart Centre Singapore, Singapore, Singapore.
Tay WT; National Heart Centre Singapore, Singapore, Singapore.
Hung CL; Mackay Memorial Hospital, Taipei, Taiwan.
Narasimhan C; Care Hospital, Hyderabad, India.
Shimizu W; Nippon Medical School's Department of Cardiovascular Medicine, Tokyo, Japan.
Park SW; Korea University Hospital, Seoul, Korea.
Liew HB; Jeffrey Cheah School Of Medicine And Health Sciences, Monash University Malaysia & Department of Cardiology, Queen Elizabeth Hospital 2, Malaysia.
Ngarmukos T; Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Reyes EB; Manila Doctors Hospital, Manila, Philippines.
Siswanto BB; National Cardiovascular Center Universitas Indonesia, Jakarta, Indonesia.
Yu CM; Heart Centre, Hong Kong Baptist Hospital, Hong Kong, SAR, The People's Republic of China.
Zhang S; Fuwai Hospital, Beijing, The People's Republic of China.
Yap J; National Heart Centre Singapore, Singapore, Singapore.
MacDonald M; Changi General Hospital, Singapore, Singapore.
Ling LH; Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road Singapore, Singapore 119228.; Cardiac Department, National University Health System, Singapore.
Leineweber K; Bayer AG, Wuppertal, Germany.
Richards AM; Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road Singapore, Singapore 119228.; National University Heart Centre, Singapore, Singapore.; Christchurch Heart Institute, University of Otago, 2 Riccarton Avenue, Christchurch 8011, New Zealand.
Zile MR; Medical University of South Carolina, and the Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA.
Anand IS; Veterans Affairs Medical Center, Minneapolis, MN, USA.
Lam CSP; National Heart Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore.; National University Heart Centre, Singapore, Singapore.
Pokaż więcej
Corporate Authors:
ASIAN-HF Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2019 Jan; Vol. 21 (1), pp. 23-36. Date of Electronic Publication: 2018 Aug 16.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Public Health*
Heart Failure/*epidemiology
Stroke Volume/*physiology
Aged ; Asia/epidemiology ; Comorbidity ; Echocardiography ; Female ; Follow-Up Studies ; Heart Failure/diagnosis ; Heart Failure/physiopathology ; Humans ; Male ; Middle Aged ; Prevalence ; Prospective Studies ; Ventricular Function, Left
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
Autorzy:
Rørth R; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Cardiovascular Medicine, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Jhund PS; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Kristensen SL; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Cardiovascular Medicine, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Desai AS; Brigham and Women's Hospital, Boston, MA, USA.
Køber L; Cardiovascular Medicine, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Rouleau JL; Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Canada.
Solomon SD; Brigham and Women's Hospital, Boston, MA, USA.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.; National Heart and Lung Institute, Imperial College, London, UK.
Zile MR; Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2019 Jan; Vol. 21 (1), pp. 40-49. Date of Electronic Publication: 2018 Dec 10.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Diabetes Mellitus, Type 2/*complications
Heart Failure/*blood
Natriuretic Peptide, Brain/*blood
Peptide Fragments/*blood
Stroke Volume/*physiology
Troponin T/*blood
Aged ; Biomarkers/blood ; Diabetes Mellitus, Type 2/blood ; Europe/epidemiology ; Female ; Heart Failure/complications ; Heart Failure/epidemiology ; Humans ; Male ; Morbidity/trends ; Prognosis ; Prospective Studies ; Risk Factors ; Survival Rate/trends
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 37

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies